Cellectar Biosciences reports promising initial results from the CLOVER-2 trial of iopofosine I 131 for pediatric high-grade glioma. Cellectar Biosciences, Inc. recently announced promising initial ...
FLORHAM PARK, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback